Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Bayview Research Group LLC

Neither a doctor nor a teaching hospital

Research payments

$10,034,296

824 payments

Through program year 2025, Bayview Research Group LLC is reported as receiving $10,034,296 in research payments, across 824 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $891,147 184
2024 Research $1,240,457 120
2023 Research $2,194,208 333
2022 Research $2,344,250 86
2021 Research $2,301,371 77
2020 Research $1,012,966 21
2019 Research $49,898 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $6,298,418 208 payments
  2. Moderna TX, Inc. $3,037,447 441 payments
  3. Astellas Pharma Global Development $256,427 58 payments
  4. Sumitomo Pharma America, Inc. $216,888 95 payments
  5. Amgen Inc. $123,973 8 payments
  6. AbbVie, Inc. $85,326 13 payments
  7. Merck Sharp & Dohme Corporation $15,818 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $2,444,490 347 payments
  2. Phase 1 Openlabel Dosefinding Study to Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults $2,311,578 44 payments
  3. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $2,276,878 83 payments
  4. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $976,244 38 payments
  5. A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $592,957 94 payments
  6. An Interventional Randomized Activecontrolled Phase 23 Study to Investigate the Safety Tolerability and Immunogenicity of Bivalent Bnt162b Rnabased Vaccine Candidates As A Booster Dose in Covid19 Vaccineexperienced Healthy Individuals $289,370 21 payments
  7. A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms $256,427 58 payments
  8. A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $255,503 9 payments
  9. A Phase 23 Protocol to Investigate the Safety Tolerability and Immunogenicity of Bnt162b2 Rnabased Vaccine Candidates for Sarscov2 New Variants in Healthy Individuals $177,526 10 payments
  10. FOURIER OLE (Ph 4) $88,136 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record